Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

PubWeight™: 1.56‹?› | Rank: Top 4%

🔗 View Article (PMID 10716151)

Published in Am J Surg Pathol on March 01, 2000

Authors

B P Nelson1, M A Nalesnik, D W Bahler, J Locker, J J Fung, S H Swerdlow

Author Affiliations

1: Department of Pathology, University of Pittsburgh School of Medicine, PA, USA.

Articles citing this

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res (2013) 3.48

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol (2010) 2.69

Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96

Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68

Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn (2001) 1.47

Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol (2011) 1.16

Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg (2002) 1.16

EBV-associated lymphomas in adults. Best Pract Res Clin Haematol (2012) 0.95

Association of early HIV viremia with mortality after HIV-associated lymphoma. AIDS (2013) 0.92

Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep (2013) 0.89

Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant (2011) 0.87

Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. J Clin Oncol (2012) 0.87

Clinical characteristics of monomorphic post-transplant lymphoproliferative disorders. J Korean Med Sci (2010) 0.85

Anaplastic lymphoma kinase (ALK) protein expressing lymphoma after liver transplantation: case report and literature review. J Clin Pathol (2002) 0.85

Avoiding pitfalls: what an endoscopist should know in liver transplantation--part II. Dig Dis Sci (2008) 0.84

Posttransplant lymphoproliferative disorders. Adv Hematol (2012) 0.78

Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage. Oncotarget (2015) 0.76

Newly emerging therapies targeting viral-related lymphomas. Curr Oncol Rep (2011) 0.76

Post cardiac transplantation T-cell lymphoproliferative disorder presenting as a solitary lung nodule. Int J Clin Exp Pathol (2013) 0.75

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto? Case Rep Med (2012) 0.75

EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations. Mod Pathol (2016) 0.75

Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders. World J Transplant (2016) 0.75

Colonic diffuse large B-cell lymphoma in a liver transplant patient with historically very low tacrolimus levels. Case Rep Transplant (2012) 0.75

Is there a difference in post-transplant lymphoproliferative disorder in adults after solid organ and haematologic stem cell transplantation? Experience in 41 patients. Br J Radiol (2015) 0.75

Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level. World J Gastroenterol (2017) 0.75

Epstein-Barr virus: general factors, virus-related diseases and measurement of viral load after transplant. Rev Bras Hematol Hemoter (2011) 0.75

Surveillance of Epstein-Barr virus infection as a risk factor for post-transplant lymphoproliferative disorder in pediatric renal transplant recipients. Pediatr Nephrol (2004) 0.75

Epstein-barr virus-negative post-transplant lymphoproliferative diseases: three distinct cases from a single center. Turk J Haematol (2014) 0.75

Posttransplant Lymphoproliferative Disorder of the Thorax: CT and FDG-PET Features in a Single Tertiary Referral Center. Medicine (Baltimore) (2015) 0.75

Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea. J Korean Med Sci (2006) 0.75

Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations. Can J Gastroenterol Hepatol (2015) 0.75

Epstein- Barr Virus: Clinical and Epidemiological Revisits and Genetic Basis of Oncogenesis. Open Virol J (2015) 0.75

p52 Activation in monomorphic B-cell posttransplant lymphoproliferative disorder/diffuse large B-cell lymphoma without BAFF-R expression. Am J Pathol (2011) 0.75

A Unique "Composite" PTLD with Diffuse Large B-Cell and T/Anaplastic Large Cell Lymphoma Components Occurring 17 Years after Transplant. Case Rep Hematol (2013) 0.75

Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management. Transplant Direct (2015) 0.75

Articles by these authors

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis. Cell (1991) 6.14

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium. J Cell Biol (1996) 3.13

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75

The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med (1995) 2.68

Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68

Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57

Analytical and preparative electrophoresis of RNA in agarose-urea. Anal Biochem (1979) 2.52

FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50

Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50

Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48

Mitochondrial nucleic acids in the petite colonie mutants: deletions and repetition of genes. Biochimie (1973) 2.45

Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38

The antibody crossmatch in liver transplantation. Surgery (1986) 2.33

The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28

Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24

Distinction of follicular hyperplasia from follicular lymphoma in B5-fixed tissues: comparison of MT2 and bcl-2 antibodies. Hum Pathol (1993) 2.24

Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22

Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22

Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20

Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20

Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12

Purification and analysis of RNA from paraffin-embedded tissues. Biotechniques (1988) 2.11

One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10

A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09

The side effects of FK 506 in humans. Transplant Proc (1990) 2.08

Treatment of fibrolamellar hepatoma with partial or total hepatectomy and transplantation of the liver. Surg Gynecol Obstet (1986) 2.07

Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04

Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99

Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95

Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94

FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94

Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88

Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86

Identification of bipotential progenitor cells in human liver development. Hepatology (1996) 1.84

Salivary gland lymphoid infiltrates associated with lymphoepithelial lesions: a clinicopathologic, immunophenotypic, and genotypic study. Hum Pathol (1997) 1.84

Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83

Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82

Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81

Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80

Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78

Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77

The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation (1988) 1.72

Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72

Transplantation. JAMA (1990) 1.71

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70

Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol (1985) 1.65

Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol (1997) 1.64

Significance of Aspergillus species isolated from respiratory secretions in the diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol (1980) 1.64

Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61

Weaning of immunosuppression in long-term liver transplant recipients. Transplantation (1995) 1.59

Incidence and risk factors associated with the development of cytomegalovirus disease after intestinal transplantation. Transplantation (1995) 1.59

The spectrum of portal vein thrombosis in liver transplantation. Ann Surg (1991) 1.58

De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant (2014) 1.57

Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57

Oral glucose tolerance test in liver recipients treated with FK 506. Transplant Proc (1990) 1.56

Liver transplantation for Wilson's disease: a single-center experience. Liver Transpl Surg (1999) 1.55

Piggyback orthotopic intestinal transplantation. Surg Gynecol Obstet (1993) 1.55

Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation (2000) 1.53

Split tolerance induced by orthotopic liver transplantation in mice. Transplantation (1994) 1.52

A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50

Human biliary epithelial cells secrete and respond to cytokines and hepatocyte growth factors in vitro: interleukin-6, hepatocyte growth factor and epidermal growth factor promote DNA synthesis in vitro. Hepatology (1994) 1.49

FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. Surgery (1991) 1.49

An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitis. Am J Transplant (2001) 1.48

Pancreas transplantation with enteric drainage under tacrolimus induction therapy. Transplant Proc (1997) 1.48

Processing of precursors of 21S ribosomal RNA from yeast mitochondria. Proc Natl Acad Sci U S A (1980) 1.46

A case-control study of hematopoietic and lymphoid neoplasms: the role of work in the chemical industry. Am J Ind Med (1997) 1.45